DARE Daré Bioscience, Inc.
$0.58
Daré Bioscience, Inc. Q3 F2026 Earnings Call Transcript
AI Conference Call Analysis
Sign in or subscribe to read.Conference Call Operator
Operator
Hello and welcome to the DARE Bioscience third quarter 2026 financial results and corporate update conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode. Following the presentation, there will be a question and answer session. Note that this webcast is being recorded at the company's request and a replay will be made available on the company's website following the end of the event. Joining us today from DARI Bioscience are Sabrina Martucci Johnson, President and Chief Executive Officer, and MarDee Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed.
MarDee Haring-Layton
Chief Accounting Officer
Good afternoon and welcome. Today we will review our financial results, provide updates on our commercial products and clinical pipelines, and discuss the continued execution of our dual path strategy. which involves commercializing proprietary formulations through 503 compounding while pursuing FDA approval and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and as quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. We should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings including our quarterly report on Form 10-Q for the quarter ended September 30, 2026, which was filed today, and our annual report on Form 10-K for the year ended December 31, 2025. Please note that the content of this call includes time-sensitive information that is current only as of today, November 16, 2026. DARI Bioscience undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call. except as required by law. I would also like to point out that when we use the term 503B compounding during this discussion, we are referring to compounding drug products by outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act using bulk drug substances on the FDA's Interim Category 1 list. I would now like to turn the call over to Sabrina.
Sabrina Martucci Johnson
President and Chief Executive Officer
Thank you, MarDee, and good afternoon, everyone, and thank you for joining us. At DARI, we have always believed that women's health deserves a business built around it, and that the health of women is an investment-grade category. That means developing products with a scientific foundation, addressing needs that have been overlooked, and creating practical ways for women to access those products. Today, you can see that strategy taking shape across our business. LoRaThink LF5 is in the market. Prescriptions for Dare to Place with NFL Cream are being written for patients across the country ahead of dispensing, and we are excited to be able to start reaching out to clinicians today to let them know that dispensing is planned to commence later this month. Two of our later stage clinical programs are progressing toward data in 2027, and our grant-supported work is creating opportunities that we believe will extend the portfolio. Our focus is on execution. Building Demand Through Trusted Healthcare Providers, Preparing Commercial Supply, Moving Our Studies Forward, and Securing an External Support that Helps Us Do More with Our Capital. For more than 10 years, DARI has been building towards this moment. We have the science, we have the commercial opportunities, and our job now is to turn them into a business that delivers for women and our shareholders. To start, I think it's important to highlight the progress we have made over just the past six months. We launched FloraSync LF5, opening our first direct-to-consumer revenue channel. We added MyMenopauseRx as a specialized telehealth option for deer to place the beneficial cream. We initiated the deer HPV phase two study and announced a new US patent expected to provide protection into at least 2039. We published new peer-reviewed Sudenifil cream data in postmenopausal women and in men, expanding our evidence-based approach. We secured additional non-dilutive support for DER-LARC1 and DER-PTB2. And our work on the DER-IDDS drug delivery platform underlying the DER-LARC1 technology has supported exploratory collaboration discussions around applications in obesity, diabetes, and other chronic conditions. and today we've announced that Dare to Place the Benefil Cream is on route to Medvantix, the central mail-order pharmacy handling prescription fulfillment to support dispensing plan to commence this month. I will discuss these areas in more detail, beginning with the continued national attention on women's health and why that matters to our development strategy. And of course, what it means that Dare to Place the Benefil Cream is on route to Medvantix to start dispensing. The new executive order on women's health calls for a dedicated NIH women's health division and a White House Women's Health Task Force. The goals include better coordination of research and federal action, with an emphasis on translating discoveries into improved care for women throughout their lives. We view this as a continuation of an important national focus across successive administrations Women's Health has been recognized as an area that requires attention, investment, and action. That continued attention may create additional non-dilutive funding and collaboration opportunities. And that has been central to our development strategy in helping us move programs forward while limiting shareholder dilution. Across our portfolio, we have been awarded more than $60 million from the Gates Foundation, $10 million through ARPA-H, and more than $5 million through NIH and NICHD-supported programs. In October, we received $1.5 million installment under our grant agreement for DARE-LARC-1, bringing total funding received under that agreement to approximately $43.3 million. We also received approximately $852,000 under our $10.7 million Gates Foundation grant for the ongoing oviprene Phase III clinical trial, and DARE and HC, which is our non-hormonal contraceptive program, bringing total funding received under that agreement to approximately $9.9 million. This funding allows us to develop a broad portfolio while directing other capital toward commercial execution and priorities outside of these funded programs. Turning to our commercial activities, let me start with FloraThink LFI, which is the first product in our Dare to Restore portfolio. Floresync LF5 is a non-hormonal probiotic vaginal capsule designed to support vaginal microbiome balance, moisture, and comfort. It's available without a prescription, and our first product sales began in July. What differentiates Floresync LF5 is the science behind it. Floresync LF5 was evaluated in a randomized clinical study involving 100 women, with results published in a peer-reviewed journal. That level of product-specific clinical research is unusual in a category where consumers frequently encounter products with limited supporting evidence. We believe this creates meaningful commercial potential. There are an estimated 46 million sexually active women in the U.S. aged 15 to 49, and one survey found that approximately 65% of women aged 18 to 65 feel insecure about their vaginal scent. We are still in the early stages of commercialization and our priority is disciplined execution. Our initial commercial focus has been clinician education and sampling. We are introducing the product to women's health providers, explaining the product-specific clinical research, and giving them an opportunity to become familiar with it. We are also beginning to receive orders from practices that want to make the product available for purchase in their offices. That creates a direct connection between a provider's recommendation and a woman's ability to access the product. Our objective is to turn those initial introductions into continued recommendations, office purchases, and repeat consumer demand. That's the commercial foundation we are building. And we are seeing evidence that this approach is working. While the revenue in the first month is not material, in the early stages of launch, we're looking at other indicators that we believe can be predictive of future performance. Specifically, we're looking at geographic reach. FloorSync LF5 orders have come from 27 states. We're looking at provider traction, and we have received our first provider office reorder. Customers are also telling us that they purchased FloraSync LF5 after receiving a recommendation or a sample from their healthcare provider. These are the connections our commercial strategy is designed to create. Clinicians introducing the product, women making a purchase, and practices returning to order again. Early consumer feedback has been very positive with a 4.9 star review rating after the initial approximately 25 reviews. As we plan for 2027, We are also evaluating additional retail channels for product discovery and reorder so that women may first hear about Florasync LF5 from their clinician or social media and then choose the purchasing channel that's most convenient for her. That includes working with Amazon. We were thrilled that Florasync LF5 was selected by Amazon for their new seller recruitment program, and we are looking forward to making the product available on Amazon in early 2027. We're also pleased to be expanding the Dare to Restore brand family to include Flora Renew and Flora Reset, a vulvar mask and cleanser both anticipated in early 2027. And I'm excited, no pun intended, to turn to Dare to Play Sedentafil Cream, our proprietary topical Sedentafil Cream formulation designed specifically for women, which we are bringing to market in collaboration with the 503 registered outsourcing facility. Product is on route today from the 503b outsourcing facility to Medvantix, which is the mail order pharmacy, and we expect prescription dispensing to begin in November. Over the last several months, our 503b facility partner has been preparing for this day, preparing to provide supply at commercial scale. And I want to spend a moment on what that means. Dare to Place and NFL Cream is not made at a compounding pharmacy one tube at a time on an individual prescription basis. We have been preparing for commercial scale production at a registered outsourcing facility operating under pharmaceutical good manufacturing practice requirements. That manufacturing process is an important part of being able to supply the product consistently at the scale that the demand requires. We know women and providers are waiting, so it is rewarding that we can start reaching out to them today to let them know that dispensing is planned to commence later this month. The underlying need remains substantial, with an estimated 20 million women in the United States alone experiencing symptoms of low or no sexual arousal. At a price of $99 per tube, which provides about 10 uses, The estimated addressable population of 20 million women represents a total market opportunity of approximately 2 billion. Even modest market penetration could create meaningful commercial value in an area with limited female-specific options. We're also continuing our dual path strategy. The 503 regulatory pathway provides a way to make the formulation available by prescription now. while we continue engaging with the FDA on the phase three development program and pursuing potential approval through the 505 regulatory pathway. While we've been preparing for dispensing, our provider outreach has been translating into written prescriptions. 182 office-based providers, not including telehealth, have already written Dare to Play prescriptions before the product is even available. If we include both office-based providers and telehealth, Prescriptions have been written across 48 states and the District of Columbia. Clinicians can also stock and dispense Dare to Play directly from their offices. And during the sexual health conference that just happened this past weekend, the first such order was received. What matters is that engagement is coming through both access channels. Office-based providers can introduce the product through an established clinical relationship. telehealth gives women another way to connect with a provider and obtain a prescription. And while it's still early, I'm encouraged by what we are seeing in terms of geography of prescriptions being written and a healthy split between office providers and telehealth, as well as repeat prescriptions from providers. Dispensing will commence in the 28 states where the outsourcing facility is currently licensed. And once dispensing begins in those states, The facility can advance the licensing process in the remaining states. We appreciate those office-based providers who wrote prescriptions for their patients and the women who have already completed their telehealth visit so that they can be the first to try Dare to Place the Benefit Cream as dispensing commences. The geographic breadth and the participation from both office-based clinicians and telehealth are encouraging, and we expect that interest is what converts into product access and revenue. We are building awareness in the places where clinicians and women are already having conversations about women's health. That includes clinician meetings, such as those hosted by the Menopause Society, Her Medicine, as well as events like WME and Stimulate that connect us with consumers, sexual health specialists, and other influential voices. Encouraging examples came at the Menopause Society meeting and the Nurse Practitioners for Women's Health meetings, where thought leaders independently discussed our products on stage, importantly, without being asked or paid by DARI to do so, or they live streamed from our exhibit booth. While anecdotal, it's a meaningful signal. It suggests our products are becoming part of the clinical conversation beyond our own reach. and that is visibility that can turn into recommendations and access. Each interaction creates an opportunity to connect women with our products and build an ongoing relationship. We're often asked about expansion to national subscription product fulfillment channels, those large telehealth platforms that have a model centered on high volume, low price access. Those platforms are built for commodity products and pricing. whereas we're building reach across several channels that we control or that align with our strengths. The DARE Health Hub, which is our own telehealth and pharmacy pathway, covered by Medvantix, which keeps the patient relationship and refill experience with us. Patients own providers. Any licensed prescriber can prescribe DARE to play or stock it and sell it through their offices. Telehealth companies that do not sell their own white label compounded products are also a great channel. Our collaboration with MyMenopauseRx is an example of that. A telehealth practice dedicated to perimenopause and menopause care serves women who are already seeking care and who value evidence-based options. We are pursuing additional similar collaborations, so stay tuned. This approach extends the Dare to Play brand across multiple platforms instead of tying it to just one. We believe it protects our pricing, avoids concentration risk, and Bill for clinical familiarity that sustains the brand's value over time. We remain open to and continue to evaluate other types of partners on terms that preserve the brand and its economics. That brings me to the connection between our commercial activities and our development pipeline. When we engage with clinicians, we are discussing needs they see across their practices. That uniquely distinguishes DARE Bioscience and our corporate brand with them. Vaginal health may be the starting point, but those conversations can extend quickly to sexual health, contraception, menopause, persistent high-risk HPV infection, the therapeutic gaps that they are looking to solve. And our portfolio reflects that breadth, and we believe it's well received. Oviprene is our investigational hormone-free monthly intravaginal contraceptive currently in a pivotal phase three study. DARE-HPV is in a Phase 2 study for persistent high-risk HPV infection. DARE to Reclaim is our estradiol and progesterone intravaginal ring with availability through the 503b compounding pathway targeted for 2027. With the FDA initiating the removal of the black box warnings from menopause hormone therapy products in November 2025, that category is reopening after two decades of under-treatment and currently Dare to Reclaim would be the only clinically-studied product delivering both hormones in a once-a-month vaginal format. That's exciting. Each program has its own development requirements and commercial path, and what they share is a focus on needs that women and their healthcare providers continue to identify as underserved. I also want to highlight one of the areas of the development pipeline that we believe has significant potential. and that is the DARE IDDS platform, which is our programmable drug delivery platform. Because it is preclinical, we often don't discuss it on these calls, but it gets a lot of attention at drug delivery conferences. DARE IDDS is the underlying drug delivery implant technology behind DARE-LARC1, our grant-supported contraceptive program. It's designed to remotely control How much drug is released and when over a period of months to years? That type of drug delivery tunability could have broad application across a range of chronic conditions. The value potential is being noted, and we are beginning to explore strategic collaboration in obesity, diabetes, hormone therapies, and neurologic disease, including potential applications with GLP-1 medicines. For DARE, this creates an important potential opportunity to extend the value of our grant-supported research into the development of new therapeutic candidates and into major markets that are getting serious attention. We have made significant progress on the commercial front, from the ongoing launch of Fluorsync LF5 for preparing for Deer-to-Play Sedanafil Cream Prescription Dispensing this month, We are also building the pipeline to support future commercial growth with Dare to Reclaim, Ovaprene, and Dare HPV. These programs represent opportunities to expand our portfolio through the provider relationships and commercial platform that we are establishing today. Our earlier stage programs provide additional opportunities over time. As I've noted, they include work in contraception, as well as preterm birth and other areas of women's health where we believe differentiated products could address And as I just highlighted, the IDDS platform technology could expand our reach beyond conditions that solely affect women. As with our late-stage portfolio, we're using external funding and collaborations to support development where possible. I'd now like to hand the call back to MarDee for a review of our financial results.
MarDee Haring-Layton
Chief Accounting Officer
Thank you, Sabrina. We ended the third quarter with approximately $11.5 million in cash and cash equivalents as of September 30, 2026 and working capital of approximately $3.2 million. Total revenue for the third quarter was approximately $48,000 compared with approximately $2,000 in the third quarter of 2025. Revenue primarily reflected research and development services. Third quarter revenue also included initial sales of FloraSync LF5, which began in July. Selling general and administrative expenses were approximately $2.6 million compared with approximately $2.5 million in the third quarter of 2025. The increase primarily relates to increases in commercial readiness expenses and personnel costs and a non-cash write-down of deferred offering costs, partially offset by decreases in general corporate overhead expenses and professional services. Research and development expense was approximately $0.3 million compared with approximately $1.2 million in the prior year period. The decrease in expenses primarily reflected lower spending across several development programs, partially offset by increased costs related to the DARE HPV program, and decreased contra-R&D expenses associated with direct program costs for grant-supported programs. Our R&D expenses reflect the impact of non-dilutive funding we receive. Our low third quarter R&D expense should be considered in that context rather than as a measure of the development activity taking place across our portfolio. Net loss for the quarter was approximately $3.2 million compared with approximately $3.6 million in the third quarter of 2025. I encourage investors to review our quarterly report on Form 10-Q for a more detailed discussion of our financial results, grant agreement, liquidity, and capital resources, as well as the risks associated with our business. Back to you, Sabrina.
Sabrina Martucci Johnson
President and Chief Executive Officer
Thank you, Marty. The priorities ahead are clear. We're working to build repeat demand for Fluorosync LF5 and to begin dispensing Deer-to-Place with NFL Cream this month. The provider engagement, written prescriptions, and early office orders, as we have discussed, give us a solid base to build from. And the next step is translating that activity into sustained commercial performance. At the same time, we're moving the Obaprene and DARE HPV clinical studies toward readouts on both programs in 2027. Non-dilutive funding continues to support that work and our earlier stage programs. and Dare IDDS gives us an additional opportunity to explore the value of potential programmable drug delivery across a broad set of chronic conditions. Our business now includes a product in the market, another preparing for dispensing this month and a pipeline that can support future growth. We intend to connect those opportunities through focused execution, trusted provider relationships and disciplined investment. That's how we're building DARI Bioscience, a company focused on bringing scientifically supported options to women and creating long-term value as those options reach the market. I will now turn the call back to the operator for questions.
Conference Call Operator
Operator
At this time, I would like to remind everyone, in order to ask a question, please press star followed by the number one on your telephone keypad. We will pause for just a moment to compile the Q&A roster. Your first question comes from the line of Jeffrey Cohen with Layden Burke Bauman. You may go ahead.
Jeffrey Cohen
Analyst, Ladenburg Thalmann
Hello, Sabrina and Marty. Thanks for taking our questions and congrats on the progress.
Sabrina Martucci Johnson
President and Chief Executive Officer
Thank you.
Jeffrey Cohen
Analyst, Ladenburg Thalmann
Two areas in particular, I guess firstly, could you talk about Fluoresce Inc. LF5? Talk about the channels there or the proceed channels in the short term will be initially through your health hub exclusively and then some expansion into Amazon early in 27. Are there other channels that you're thinking about at the moment?
Sabrina Martucci Johnson
President and Chief Executive Officer
Yeah, that's a great question. So regarding Floresync LF5, you've summarized that near-term initiative perfectly, which is right now the product is available through the DARE Health Hub as well as in clinician offices. So we do have clinician offices that have begun to stock and sell the product directly in their offices. So those are both great channels for us. Amazon is the first. Broad Retail Channel that we are going to be available on. And as we mentioned, we're really excited about how this came to be. We've been looking at where women go for products like this. Particularly, as we mentioned, we want to make sure that when they get that recommendation from their healthcare provider or maybe they see it online, we want to make sure that they have available, right, a purchasing channel that's most convenient for them. and Amazon has a fantastic new seller recruitment program where they actually, they look for brands that they think have exciting potential and meet the needs of the demographics that they serve. And so we were really thrilled that there was a match for not just like Flores Inc. LF5, but as we extend the Dare to Restore brand family. So yes, that's a channel that we are working on for early 2027. In addition, though, we are looking at other channels, right? We want to make sure that wherever she hears about this, it's really easy for her to get access to it. So this could be other online channels where products like this would be available, and this would be a really great fit in terms of demographics of the people that buy through those channels. as well as we are looking at different, you know, think of it like brick and mortar retail options as well for later rollout.
Jeffrey Cohen
Analyst, Ladenburg Thalmann
Got it. Would you anticipate that renew and reset to follow in those steps with similar channels as for?
Sabrina Martucci Johnson
President and Chief Executive Officer
Yes. Yes. 100%.
Jeffrey Cohen
Analyst, Ladenburg Thalmann
Yes. Okay. And then secondly, I wanted to jump back to Could you talk a little bit about physicians and office prescribers there as far as how that's looking and how that's rolling out and also talk to us about those channels as well outside of office prescribers?
Sabrina Martucci Johnson
President and Chief Executive Officer
Yeah, so with Deer to Play Sedentifil Cream, this one is prescription. So FloraSync LF5 is non-prescription. So obviously that opens up some different channels that would not be great options for Deer to Play Sedentifil Cream. So Deer to Play Sedentifil Cream is available through the Deer Health Hub. On the Deer Health Hub, we have our own telehealth available. So if someone goes to the hub and she does not already have a prescription, she can do an asynchronous. It takes about 10 minutes. questionnaire visit to see if Dear Deplaced Info Cream is an appropriate fit for her. So she can do that on the Dear Health Hub. If she already has a relationship with the clinician, that clinician has a couple options. They can submit the prescription through the Dear Health Hub and have it fulfilled that way, or they can also make a determination to purchase the product directly and then sell it and dispense it directly in their offices. And so that's a channel that's available as well and we have a provider already set up to do that and there'll be others. We're also though looking at other, as I mentioned, other opportunities to make for the product where again women are going to get their products. One collaboration that we highlighted today was with MyMenopauseRx. That's an example of a telehealth practice that does not sell any products, but they really focus on perimenopause and menopause care services to women who are seeking them and who really value their evidence-based options. So expect to see other relationships like that that we are pursuing and are starting to set up. The other is really looking at, again, different places where women are going to get products like this. We talked a little bit about different types of national subscription models, but those are varied in their approach, in how they're set up, and the kind of products that they offer. So there are some of those models that could be appropriate for this product as well. And bottom line is we want to make sure that Dare to Place and InfoCream is meets a few criteria. It's available where she is conveniently going to get the product, but that it also ties to what we are focusing on for the product, right, where we have the credible science, we want to protect our pricing, we want to avoid any kind of concentration risk, and we want to make sure that it's building on what really distinguishes this product, which is the clinical data and the clinical comfort behind it. So more to come. So stay tuned.
Jeffrey Cohen
Analyst, Ladenburg Thalmann
Super. Thanks for taking our questions.
Sabrina Martucci Johnson
President and Chief Executive Officer
Thank you.
Jeffrey Cohen
Analyst, Ladenburg Thalmann
Great questions.
Conference Call Operator
Operator
Our next question comes from the line of Kemp Dolliver with Brookline Capital Markets. Please go ahead.
Kemp Dolliver
Analyst, Brookline Capital Markets
Hi. Good afternoon. And first couple questions on Dennis Phil, if you prefer dare to play. What's the existing market size since there are a couple of competing products on the market?
Sabrina Martucci Johnson
President and Chief Executive Officer
Yeah, in terms of the, there's no competing product in the sense that there is literally another product that has the clinical evidence that this is really a first of its kind in terms of having demonstrated that it increases blood flow within 10 to 15 minutes of application. that has the data indicating an improvement in arousal response using clinically validated FDA-reviewed endpoints. So it's very much unique in that perspective. In terms of 503A compounded or, you know, compounded stand-in for creams, they are available. They are out there. They're really not comparable to this product, and that really comes across when we're talking to those women and healthcare providers in terms of what they're looking for. There are no data in terms of, it's not like IMS data or IQVIA data as we would say now in terms of where you can go and find that kind of prescription level marketplace data. What we do know and what I highlighted is that through the work we've done and this has been really backed in other studies around sexual, there are around a million women estimated in the United States that are not happy with their physical arousal response. They're experiencing symptoms of low or no sexual arousal, physical and in nature. And so when we look at that and then we take the price of the tube, which is about $100, $99 per tube, that's how we get at that total market opportunity of approximately $2 billion. In terms of sizing the total addressable market, that's really the best we can do right now with the data that are available.
Kemp Dolliver
Analyst, Brookline Capital Markets
Thank you. Also, how many states allow physicians to prescribe and dispense prescription drugs? Honestly, there are very few countries on the planet that allow that. I'm sure you're following the law, so I'm curious how the size of this channel is.
Sabrina Martucci Johnson
President and Chief Executive Officer
Yeah, so it's really, so first of all, from a 503 outsourcing facility, it's actually one of the reasons that the 503 outsourcing facility regulations were put into place for recognition that hospital systems and clinician practices are maybe certain and many other medicines that it makes sense for them to have available and to provide at a larger scale than what would be allowed through 503A pharmacy compounding on a named individual, named patient basis. So that's really one of the things that it was really designed for. In terms of where that can happen today, it really is based on, as you noted, kind of state level regulations. But really the key regulation behind that is The 503b Outsourcing Facility is licensed to operate. That, first and foremost, is where we have to focus our attention, and right now that's 28 states.
Kemp Dolliver
Analyst, Brookline Capital Markets
Great. Thank you. And the last question, as you roll out these products, are you going, I forget, if you're going to be carrying the inventory and holding it on your books, or if it's strictly going to be at the Compounding Pharmacy.
Sabrina Martucci Johnson
President and Chief Executive Officer
It's a little bit different if we're talking about Dare to Place and NFL Cream versus the Dare to Restore, Fluorosync, LF5 family of those products. When we're talking about those products, that is our inventory. Those are non-prescription products, and that product inventory is ours. When we're talking about Dare to Place and NFL Cream, that is not our inventory. We are not the 503 outsourcing facility. So that inventory belongs to that 503bioscience facility. And it's a great opportunity to talk a little bit about, you know, what one could expect to see in terms of our financial statements, right, when it comes to deer-to-place. It's really going to be that net... Net of the cost associated. That's really what we would be receiving. So it's net of the cost at the 503B outsourcing facility. It's net of the cost at the Medantic, which think of that as both your party logistics and your pharmacy dispensing. So not dissimilar for what you would see for any typical prescription product. But what we'll be booking is the net proceeds, net of all that. and so that was a long answer of no, we do not hold that inventory.
Kemp Dolliver
Analyst, Brookline Capital Markets
But you will on the prescription products?
Sabrina Martucci Johnson
President and Chief Executive Officer
No, we will not on the prescription products. On the non-prescription, correct.
Kemp Dolliver
Analyst, Brookline Capital Markets
Okay, great. Thanks, I got that.
Conference Call Operator
Operator
Yep. Your final question comes from the line of Douglas Stout with H.C. Wainwright. Please go ahead.
MarDee Haring-Layton
Chief Accounting Officer
Hi, good afternoon. Thanks for taking the questions. Sabrina, I guess I'm just curious, when you think about the addition of new platforms, when you think about what something like Amazon offers versus some of the other sort of subscription-based products or platforms, is there another vertical that you think you need to add or would be advantageous?
Sabrina Martucci Johnson
President and Chief Executive Officer
That's a great question. As we take a step back, right, I'm actually at the health conference right now that's happening in Las Vegas, and I, right before this call, sat in on a session around longevity. And we are not in the, you know, we don't sometimes think of ourselves in the longevity business, but when we think about the kind of things we do, we're making people's lives better. That's a lot of what that's about. And one of the points that came out of the session that I sat in right before was really around this question around where are people getting their products and how do we find that balance between making sure that the solutions that people need are available to them in the places where they are going for care. At the same time, how do we find that balance between making sure that our products are on platforms where there are other products like ours, clinically studied, evidence-based solutions that are trusted, but making sure that we're meeting the consumer where they are because right now the challenge has been the medicine is not necessarily keeping up with the conversation and the consumer demands. The consumer demands are there, but the solutions that are truly studied that a healthcare provider can get behind just as well as a consumer can get behind are not always available. And so as we're looking at different channel strategies, the short answer to your question is yes. There are other places that we think our products should be, and we are working on those. So they're not limited to the channels that we're rolling out initially. But I also want to go back to one of the first comments I made kind of early in the call, which is about our discipline execution. Right now, whether we're talking about Fluorosync, LF5, or we're talking about Dare to Place and NSO Cream, the first thing we're doing is making sure that healthcare providers, clinicians, and clinicians writ large, broadly, right, nurse practitioners, MDs, sex therapists, pelvic floor specialists, right? The people that will come in contact with women where our products can be beneficial are hearing the clinical story and the scientific message behind the product so that they're ready, right? Think of it as even like floor things, not a prescription product, but the mindset is the same. It has nice data behind it, and we want to make sure that the clinician has heard about it in a variety of channels, and that also means existing other telehealth channels. and so we're starting with that but we will continue you'll continue to see us bolting on additional places where our products are available because as we continue to do the work we find that those are places where the women who are perfect fit for our products are going for their solutions. I think as it comes to Floristic LF5 Amazon is a fantastic next step for that both because of the program that we get to be a part of and the support behind that for the brand, which will be great. But also that is the sort of obvious, if you think about reach and breadth, next channel for this product to be available so that if she's hearing about it from her clinician or on social media, it's a very standard, you know, typical place where someone can go for a product like this.
MarDee Haring-Layton
Chief Accounting Officer
Okay, great. Thank you very much. That's super helpful.
Conference Call Operator
Operator
This concludes the question and answer session. I would now like to turn the call back to Sabrina Johnson.
Sabrina Martucci Johnson
President and Chief Executive Officer
Thank you so much. And as we close, I just really want to share my confidence in what we're building here at Dari Bioscience and put it in perspective. For years, our team has worked to develop options around needs that women have been asking the healthcare industry to address. And I believe we're answering that call. There's more to do and we're definitely, as we've been talking about, focused on execution. Our responsibility is to turn the scientific and the commercial opportunities that we've been generating and that are in front of us into a business that delivers for women and our shareholders. And that remains our commitment as we move through the remainder of 2026 and importantly into 2027. Thank you.
Conference Call Operator
Operator
Ladies and gentlemen, this concludes today's call. You may now disconnect.